Fundraising Fox

Entero Therapeutics

St. Petersburg, US · Founded 2014 · Delaware corporation

Biotech

Founders & leadership

RP
Richard PaoloneExecutive
AS
Anna SkowronExecutive
J(
Johan (Thijs) SpoorExecutive

Board

MB
Matthew BalkBoard director
GP
Geordan PursgloveBoard director
JS
Jason SawyerBoard director
MU
Manpreet UppalBoard director
EB
Edward BorkowskiBoard director
JS
Jack SyageBoard director
EC
Eric CorbettBoard director
AR
Alastair RiddellBoard director
MS
Maged ShenoudaBoard director

Reported raises · per SEC filings

Form D private placements

$66.7M disclosed across 17 rounds · 2014–2026

▶$8.5MraisedJul 2026 · 6 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • JASON SAWYERExecutive Officer, Director
  • ED BORKOWSKIDirector
  • MANPREET UPPALDirector
  • GEORDAN PURSGLOVEDirector
  • JACK SYAGEDirector
  • Anna SkowronExecutive Officer
Offering amount
$8.5M
Amount sold
$8.5M
First sale
Jul 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.5MraisedMay 2026 · 4 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • ED BORKOWSKIDirector
  • MANPREET UPPALDirector
  • JASON SAWYERExecutive Officer, Director
  • GEORDAN PURSGLOVEDirector
  • JACK SYAGEDirector
Offering amount
$2.5M
Amount sold
$2.5M
First sale
May 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.3MraisedMay 2026 · 4 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • JASON SAWYERExecutive Officer, Director
  • ED BORKOWSKIDirector
  • GEORDAN PURSGLOVEDirector
  • JACK SYAGEDirector
  • MANPREET UPPALDirector
Offering amount
$5.3M
Amount sold
$5.3M
First sale
May 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3MraisedAug 2025 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Geordan PursgloveDirector
  • Jason SawyerDirector
  • Manpreet UppalDirector
  • Edward BorkowskiDirector
  • Jack SyageDirector
  • Eric CorbettDirector
  • Richard PaoloneExecutive Officer, Director
  • Anna SkowronExecutive Officer
Offering amount
$3M
Amount sold
$3M
First sale
Aug 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.5MraisedSep 2023 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Alastair RiddellDirector
  • Sarah RomanoExecutive Officer
  • Terry CoelhoDirector
  • Charles CasamentoDirector
  • James SapirsteinExecutive Officer, Director
  • Edward BorkowskiDirector
Offering amount
$1.5M
Amount sold
$1.5M
Sales commissions
$220K
Placement agents
Roth Capital Partners, LLC
First sale
Sep 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$431.1KraisedJun 2023 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Terry CoelhoDirector
  • Sarah RomanoExecutive Officer
  • David HoffmanDirector
  • Charles CasamentoDirector
  • Alastair RiddellDirector
  • Edward BorkowskiDirector
  • James SapirsteinExecutive Officer, Director
Offering amount
$431.1K
Amount sold
$431.1K
Sales commissions
$150K
Placement agents
Roth Capital Partners, LLC
First sale
Jun 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4MraisedMar 2023 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Charles CasamentoDirector
  • Sarah RomanoExecutive Officer
  • James SapirsteinExecutive Officer, Director
  • Terry CoelhoDirector
  • Alastair RiddellDirector
  • David HoffmanDirector
  • Edward BorkowskiDirector
Offering amount
$4M
Amount sold
$4M
Sales commissions
$180K
Placement agents
Roth Capital Partners, LLC
First sale
Mar 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.5MraisedDec 2022 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Charles CasamentoDirector
  • James SapirsteinExecutive Officer, Director
  • David HoffmanDirector
  • Terry CoelhoDirector
  • Sarah RomanoExecutive Officer
  • Alastair RiddellDirector
  • Edward BorkowskiDirector
Offering amount
$2.5M
Amount sold
$2.5M
Sales commissions
$175K
Placement agents
H.C. Wainwright & Co. LLC
First sale
Nov 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Entero Therapeutics Raises $3M Through Strategic Private Placement: GI Disease Treatment Developer Expands Fundingstocktitan.net · Aug 2025Entero Therapeutics raises $3 million through warrant offering By Investing.cominvesting.com · Aug 2025Entero Therapeutics Secures $2 Million Loan and Appoints New Board Members | ENTO Stock Newsquiverquant.com · Feb 2025Entero Therapeutics Gets $2 Million Revolving Loan, Appoints 3 New Board Members -February 07, 2025 at 04:04 pm EST | MarketScreenermarketscreener.com · Feb 2025

Frequently asked questions

How much funding has Entero Therapeutics raised?
Entero Therapeutics has disclosed $66.7M raised across 17 rounds.
Where is Entero Therapeutics headquartered?
Entero Therapeutics is headquartered in St. Petersburg, US.